Crossmark

TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models

Crossref DOI link: https://doi.org/10.1038/s41598-024-70594-1

Published Online: 2024-09-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mitsukawa, Kayo

Terada, Michiko

Yamada, Ryuji

Monjo, Taku

Hiyoshi, Tetsuaki

Nakakariya, Masanori

Kajita, Yuichi

Ando, Tatsuya

Koike, Tatsuki

Kimura, Haruhide
Funding

Funding for this research was provided by:

Takeda Pharmaceutical Company
License Information

Text and Data Mining valid from 2024-09-06

Version of Record valid from 2024-09-06
More Information

Article History

Received: 15 May 2024

Accepted: 19 August 2024

First Online: 6 September 2024

Competing interests

: All authors are or were employees of Takeda Pharmaceutical Company Limited at the time of the study and own stock or stock options.

Document is current

Any future updates will be listed below